TLS data
 

BioCommunique

Corporate Newsletter

 
 
Hear from JP Morgan Conference veteran attendees on how to take advantage of the four jam-packed days.

JPM 101: Navigating the JPM Conference Week in San Francisco

  • Fri Nov 09 07:09:00 GMT 2018
  • Bay Area
  • Author Emily Abraham

Join us on Friday, November 16th at JLABS-SSF as we learn from veteran JP Morgan Conference attendees how best to navigate all the activities happening in and around the conference that takes place in San Francisco January 8th-11th, 2019. Veteran conference navigators, Carolyn Corner, Managing Director at Westwicke Partners, Bill Newell, CEO at Sutro Biopharma, and Lesley Stolz, Head of JLABS CA, Johnson & Johnson Innovation, JLABS, will share their insights and strategies for making the most of this important networking week.  The discussion will focus on how to decide who to meet with, how to make initial connections, how to schedule your meetings, and how to make sense of all the events taking place around the actual JP Morgan conference. Entrepreneurs, Business Development and Corporate Development professionals will not want to miss this panel discussion. Register at JLABS here.

 
 

Stay in the know with the Biocommunique

Sign up for Biocom's bi-weekly newsletter to get all the latest life science news sent directly to your inbox.

 
 

Related Articles View All

https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2anWQAR&oid=00DA0000000Kz7JMAS  
Apply now for UC San Diego's new program which gives fellows experiences in sharing the university's health science news with the public.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2an2QAB&oid=00DA0000000Kz7JMAS  
Hear from Eric Topol, MD and Abraham Verghese, MD on latest trends in AI in medicine, rare disease, oncology and more.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2KtKQAV&oid=00DA0000000Kz7JMAS  
Genentech, a subsidiary of Roche, took a dive into the $20 billion NASH market with the acquisition of San Diego-based Biocom member, Jecure Therapeutics, a company with a portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
https://www.biocom.org/servlet/servlet.ImageServer?id=0155A00000A2EyUQAV&oid=00DA0000000Kz7JMAS  
Ferring accesses Evotec's integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates.